These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27259267)

  • 61. Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment.
    Marchesi I; Fais M; Fiorentino FP; Bordoni V; Sanna L; Zoroddu S; Bagella L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408939
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
    Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
    Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
    Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
    Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
    [TBL] [Abstract][Full Text] [Related]  

  • 67. BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma.
    Wang M; Zhao L; Tong D; Yang L; Zhu H; Li Q; Zhang F
    Int Immunopharmacol; 2019 Nov; 76():105921. PubMed ID: 31600692
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of methyl isoxazoleazepines as inhibitors of BET.
    Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
    Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
    Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
    Baud MGJ; Lin-Shiao E; Cardote T; Tallant C; Pschibul A; Chan KH; Zengerle M; Garcia JR; Kwan TT; Ferguson FM; Ciulli A
    Science; 2014 Oct; 346(6209):638-641. PubMed ID: 25323695
    [TBL] [Abstract][Full Text] [Related]  

  • 72. BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.
    Zhou Y; Zhou J; Lu X; Tan TZ; Chng WJ
    BMC Cancer; 2018 Jul; 18(1):731. PubMed ID: 29996811
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 76. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
    Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
    Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.